GlassScriptPhysician profile
John Michael Mauric
NPI 1891731659
$1,466.83
in general payments reported to CMS, 2019-2025
32 companies · $157 in 2025
The $157 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $75.74 · 2021: $349 · 2022: $403 · 2023: $229 · 2024: $77.75 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $463.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $304.08 | 2021-2025 | |
| Inspire Medical Systems, INC. | $150.81 | 2022 | |
| Glaxosmithkline, LLC. | $138.73 | 2019-2023 | Shingrix |
| Lilly USA, LLC | $129.04 | 2021-2023 | Mounjaro, Emgality, Jardiance |
| Merck Sharp & Dohme LLC | $84.87 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.89 | 2021 | |
| Organogenesis INC. | $50.54 | 2025 | Apligraf |
| Boston Scientific Corporation | $41.89 | 2019 | |
| Alkermes, INC. | $38.51 | 2022 | |
| Allergan, INC. | $37.51 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $34.69 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $32.54 | 2022-2024 | |
| Gilead Sciences, INC. | $30.76 | 2019 | |
| Novo Nordisk INC | $28.08 | 2019-2021 | |
| Pfizer INC. | $27.32 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $26.41 | 2025 | Nuzyra |
| Dexcom, INC. | $24.84 | 2025 | Dexcom G6 Transmitter |
| Mimedx Group, INC. | $23.28 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.23 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.45 | 2021 | |
| Quidel Corporation | $16.43 | 2019 | |
| Medtronic, INC. | $16.43 | 2022 | |
| Dynavax Technologies Corporation | $16.30 | 2022 | |
| Solventum Corporation | $15.77 | 2025 | Promogran Prisma, Activ.A.C. |
| Amarin Pharma, INC. | $15.23 | 2020 | |
| Lundbeck LLC | $13.15 | 2023 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $12.38 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.31 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.99 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.56 | 2019 | |
| Janssen Biotech, INC. | $11.32 | 2020 | |
| Organon LLC | $9.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mauric listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.